Zoltán Kaló1, József Bodrogi2, Imre Boncz3, Csaba Dózsa4, Gabriella Jóna5, Rita Kövi5, Zsolt Pásztélyi6, Balázs Sinkovits7. 1. Health Economics Research Centre, Eötvös Loránd University (ELTE), Budapest, Hungary; Syreon Research Institute, Budapest, Hungary. Electronic address: kalo@tatk.elte.hu. 2. Independent Senior Health Economist, Budapest, Hungary. 3. Faculty of Health Sciences, University of Pécs, Pécs, Hungary; Faculty of Economics, Health Economics and Health Technology Assessment Research Centre, Corvinus University of Budapest, Budapest, Hungary. 4. Health Care Faculty, University of Miskolc, Miskolc, Hungary. 5. National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary. 6. Railway Health Services, Budapest, Hungary. 7. AstraZeneca, Budapest, Hungary.
Abstract
OBJECTIVES: Middle-income countries often have no clear roadmap for implementation of health technology assessment (HTA) in policy decisions. Examples from high-income countries may not be relevant, as lower income countries cannot allocate so much financial and human resources for substantiating policy decisions with evidence. Therefore, HTA implementation roadmaps from other smaller-size, lower-income countries can be more relevant examples for countries with similar cultural environment and economic status. METHODS: We reviewed the capacity building process for HTA implementation in Hungary with special focus on the role of ISPOR Hungary Chapter. RESULTS: HTA implementation in Hungary started with capacity building at universities with the support of the World Bank in the mid 90's, followed by the publication of methodological guidelines for conducting health economic evaluations in 2002. The Hungarian Health Economics Association (META) - established in 2003 - has been recognized as a driving force of HTA implementation. META became the official regional ISPOR Chapter of Hungary in 2007. In 2004 the National Health Insurance Fund Administration made the cost-effectiveness and budget impact criteria compulsory prior to granting reimbursement to new pharmaceuticals. An Office of Health Technology Assessment was established for the critical appraisal of economic evaluations submitted by pharmaceutical manufacturers. In 2010 multicriteria decision analysis was introduced for new hospital technologies. CONCLUSION: The economic crisis may create an opportunity to further strengthen the evidence base of health care decision-making in Hungary. In the forthcoming period ISPOR Hungary Chapter may play an even more crucial role in improving the standards of HTA implementation and facilitating international collaboration with other CEE countries.
OBJECTIVES: Middle-income countries often have no clear roadmap for implementation of health technology assessment (HTA) in policy decisions. Examples from high-income countries may not be relevant, as lower income countries cannot allocate so much financial and human resources for substantiating policy decisions with evidence. Therefore, HTA implementation roadmaps from other smaller-size, lower-income countries can be more relevant examples for countries with similar cultural environment and economic status. METHODS: We reviewed the capacity building process for HTA implementation in Hungary with special focus on the role of ISPOR Hungary Chapter. RESULTS: HTA implementation in Hungary started with capacity building at universities with the support of the World Bank in the mid 90's, followed by the publication of methodological guidelines for conducting health economic evaluations in 2002. The Hungarian Health Economics Association (META) - established in 2003 - has been recognized as a driving force of HTA implementation. META became the official regional ISPOR Chapter of Hungary in 2007. In 2004 the National Health Insurance Fund Administration made the cost-effectiveness and budget impact criteria compulsory prior to granting reimbursement to new pharmaceuticals. An Office of Health Technology Assessment was established for the critical appraisal of economic evaluations submitted by pharmaceutical manufacturers. In 2010 multicriteria decision analysis was introduced for new hospital technologies. CONCLUSION: The economic crisis may create an opportunity to further strengthen the evidence base of health care decision-making in Hungary. In the forthcoming period ISPOR Hungary Chapter may play an even more crucial role in improving the standards of HTA implementation and facilitating international collaboration with other CEE countries.
Authors: Benjamin S C Uzochukwu; Chinyere Okeke; Niki O'Brien; Francis Ruiz; Issiaka Sombie; Samantha Hollingworth Journal: Global Health Date: 2020-07-08 Impact factor: 4.185
Authors: Zoltán Kaló; Adrian Gheorghe; Mirjana Huic; Marcell Csanádi; Finn Boerlum Kristensen Journal: Health Econ Date: 2016-01-14 Impact factor: 3.046
Authors: Ahmad Fasseeh; Rita Karam; Mouna Jameleddine; Mohsen George; Finn Børlum Kristensen; Abeer A Al-Rabayah; Abdulaziz H Alsaggabi; Maha El Rabbat; Maryam S Alowayesh; Julia Chamova; Adham Ismail; Sherif Abaza; Zoltán Kaló Journal: Front Pharmacol Date: 2020-02-21 Impact factor: 5.810
Authors: Sándor Kovács; Bertalan Németh; Dalma Erdősi; Valentin Brodszky; Imre Boncz; Zoltán Kaló; Antal Zemplényi Journal: Appl Health Econ Health Policy Date: 2022-01-18 Impact factor: 3.686